A Clinical Study On Prostate Cancer Diagnosis With CDNA Chip

Prostate cancer (PCa) and benign prostate hyperplasia (BPH) are two commom diseases for the elder men. In China 13.6% of the elder men suffered from BPH, and PCa accounts for approximately 13% of all cancer deaths in America. In clinical, PSA is used for diagnosis of PCa, however, as a reslut of the insufficent specifity of PCa, elevated serum PSA levels may be the outcomes of prostatitis and BPH, even breast cancer. In particularly, it is diificult to distinguish PCa from BPH when serum PSA level is at 4～10 ng/ml. So searching more specific biomarkers for PCa is pressing.PCa is heterogeneous in nature, and is prone to heredity and enviroment factors. Virtually it is impossible to diagnosis PCa accurately by using a single biomarker. With the DNA micoarray and other biologic techniques being available, more and more PCa related genes show promises as alteratives to PSA. Harnessing the current research results, we pre-chose 9 genes (KLK3/PSA, KLK2, KLK11, pim-1, hepsin, PSMA, AR, p27, IGF-1) as a biomarker combination to advance clinical trial on PCa tests. In this study, we designed primers for 10 genes, includingβ-actin as internal control, then cloned these gene probes into pGEM-T easy vector. DNA mini array with these gene probes and real time RT-PCR with SYBR Green I are carried out to detect the mRNA expression levels of these genes in clinical samples of 25 cases. The results showed the PCa and BPH samples can be classified by the 10 genes expression profile, and among the 10 genes, KLK2, pim-1, AR and IGF-1 have the core contribution to classification.